DK3215133T3 - Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog - Google Patents
Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog Download PDFInfo
- Publication number
- DK3215133T3 DK3215133T3 DK15798601.9T DK15798601T DK3215133T3 DK 3215133 T3 DK3215133 T3 DK 3215133T3 DK 15798601 T DK15798601 T DK 15798601T DK 3215133 T3 DK3215133 T3 DK 3215133T3
- Authority
- DK
- Denmark
- Prior art keywords
- nanous
- surfactive
- rapalog
- carriers
- substances
- Prior art date
Links
- 239000000969 carrier Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000000126 substance Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0003—Invertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cosmetics (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462075866P | 2014-11-05 | 2014-11-05 | |
| US201462075864P | 2014-11-05 | 2014-11-05 | |
| PCT/US2015/059349 WO2016073798A1 (en) | 2014-11-05 | 2015-11-05 | Methods and compositions related to the use of low hlb surfactants in the production of synthetic nanocarriers comprising a rapalog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3215133T3 true DK3215133T3 (da) | 2021-02-01 |
Family
ID=54697646
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21156943.9T DK3906918T3 (da) | 2014-11-05 | 2015-11-05 | Fremgangsmåder og sammensætninger i forbindelse med syntetiske nanobærere med rapamycin i en stabil, supermættet tilstand |
| DK15857076.2T DK3215192T3 (da) | 2014-11-05 | 2015-11-05 | Fremgangsmåder og sammensætninger i forbindelse med syntetiske nanobærere med rapamycin i en stabil, supermættet tilstand |
| DK20204014.3T DK3834823T3 (da) | 2014-11-05 | 2015-11-05 | Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog |
| DK15798601.9T DK3215133T3 (da) | 2014-11-05 | 2015-11-05 | Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21156943.9T DK3906918T3 (da) | 2014-11-05 | 2015-11-05 | Fremgangsmåder og sammensætninger i forbindelse med syntetiske nanobærere med rapamycin i en stabil, supermættet tilstand |
| DK15857076.2T DK3215192T3 (da) | 2014-11-05 | 2015-11-05 | Fremgangsmåder og sammensætninger i forbindelse med syntetiske nanobærere med rapamycin i en stabil, supermættet tilstand |
| DK20204014.3T DK3834823T3 (da) | 2014-11-05 | 2015-11-05 | Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20160128987A1 (da) |
| EP (6) | EP3834823B1 (da) |
| JP (5) | JP6912377B2 (da) |
| KR (2) | KR102656139B1 (da) |
| CN (5) | CN113244191A (da) |
| AU (4) | AU2015342969B2 (da) |
| BR (3) | BR112017008720A2 (da) |
| CA (2) | CA2966850C (da) |
| CY (1) | CY1124418T1 (da) |
| DK (4) | DK3906918T3 (da) |
| EA (2) | EA201790978A1 (da) |
| ES (2) | ES2846809T3 (da) |
| FI (2) | FI3834823T3 (da) |
| HR (1) | HRP20210098T1 (da) |
| HU (3) | HUE054894T2 (da) |
| IL (7) | IL296246A (da) |
| LT (1) | LT3215133T (da) |
| MX (4) | MX2017005904A (da) |
| PL (1) | PL3215133T3 (da) |
| PT (1) | PT3215133T (da) |
| RS (1) | RS61359B1 (da) |
| SI (1) | SI3215133T1 (da) |
| WO (2) | WO2016073799A1 (da) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA022699B1 (ru) | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | НАЦЕЛЕННЫЕ СИНТЕТИЧЕСКИЕ НАНОНОСИТЕЛИ С pH-ЧУВСТВИТЕЛЬНЫМ ВЫСВОБОЖДЕНИЕМ ИММУНОМОДУЛИРУЮЩИХ СРЕДСТВ |
| CA2798493A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Synthetic nanocarrier combination vaccines |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| US9289476B2 (en) | 2011-04-29 | 2016-03-22 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| KR20140050698A (ko) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | 체액성 및 세포독성 t 림프구(ctl) 면역 반응을 발생시키는 합성 나노운반체 |
| JP7028556B2 (ja) | 2013-05-03 | 2022-03-02 | セレクタ バイオサイエンシーズ インコーポレーテッド | 特定の薬力学的有効期間および免疫寛容の誘発のための抗原を有する免疫抑制剤の送達 |
| WO2015025538A1 (ja) * | 2013-08-20 | 2015-02-26 | サンノプコ株式会社 | バイオエタノール発酵工程用添加剤及びバイオエタノールの製造方法 |
| US10071114B2 (en) | 2014-09-07 | 2018-09-11 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| US10125378B2 (en) * | 2015-02-17 | 2018-11-13 | San Nopco Ltd. | Additive for bioethanol fermentation process and method for producing bioethanol |
| US10973925B2 (en) * | 2015-04-28 | 2021-04-13 | University Of Central Florida Research Foundation Inc. | Methods and compositions for theranostic nanoparticles |
| MX2018011012A (es) | 2016-03-11 | 2019-03-28 | Selecta Biosciences Inc | Formulaciones y dosis de uricasa pegilada. |
| KR102341902B1 (ko) * | 2016-09-09 | 2021-12-21 | 카오카부시키가이샤 | 디카르복실산 결정 및 그 제조 방법 |
| US20180085319A1 (en) | 2016-09-27 | 2018-03-29 | Takashi Kei Kishimoto | Methods and compositions for treating cancer |
| BR112019013862A2 (pt) | 2017-01-07 | 2020-04-14 | Selecta Biosciences Inc | dosagem padrão de imunossupressores acoplados a nanocarreadores sintéticos |
| US11426451B2 (en) | 2017-03-11 | 2022-08-30 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2019075360A1 (en) | 2017-10-13 | 2019-04-18 | Selecta Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES |
| JP2022531201A (ja) | 2019-04-28 | 2022-07-06 | セレクタ バイオサイエンシーズ インコーポレーテッド | ウイルス導入ベクターに対する既存の免疫を伴う対象の処置のための方法 |
| CA3141863A1 (en) | 2019-05-28 | 2020-12-03 | Selecta Biosciences, Inc. | Methods and compositions for attenuated anti-viral transfer vector immune response |
| CA3138071A1 (en) | 2019-06-04 | 2020-12-10 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| JP2022553345A (ja) | 2019-10-21 | 2022-12-22 | セレクタ バイオサイエンシーズ インコーポレーテッド | 肝疾患および肝障害を処置するための方法および組成物 |
| US20210187081A1 (en) | 2019-11-08 | 2021-06-24 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| AU2021225955A1 (en) | 2020-02-26 | 2022-09-22 | Selecta Biosciences, Inc. | Methods and compositions using synthetic nanocarriers comprising immunosuppressant |
| KR20220152263A (ko) * | 2020-03-11 | 2022-11-15 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노담체와 관련된 방법 및 조성물 |
| US20230147052A1 (en) | 2020-04-14 | 2023-05-11 | Selecta Biosciences, Inc. | Methods and compositions for inducing autophagy |
| AU2021373792A1 (en) | 2020-11-04 | 2023-06-08 | Selecta Biosciences, Inc. | Compositions for reducing immune responses against immunoglobulin proteases |
| CA3207247A1 (en) | 2021-01-05 | 2022-07-14 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| KR102304785B1 (ko) | 2021-03-26 | 2021-09-24 | (주)진성티앤피 | 정밀광학기기의 부품 제조 방법 |
| EP4319747A1 (en) | 2021-04-09 | 2024-02-14 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| US20230140196A1 (en) | 2021-10-12 | 2023-05-04 | Selecta Biosciences, Inc. | Viral vector dosing protocols |
| WO2023064367A1 (en) | 2021-10-12 | 2023-04-20 | Selecta Biosciences, Inc. | Methods and compositions for attenuating anti-viral transfer vector igm responses |
| CA3237037A1 (en) | 2021-11-14 | 2023-05-19 | Cartesian Therapeutics, Inc. | Multiple dosing with viral vectors |
| US20230263906A1 (en) | 2022-01-10 | 2023-08-24 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing |
| US20230322884A1 (en) | 2022-03-09 | 2023-10-12 | Selecta Biosciences, Inc. | Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing |
| WO2023172624A1 (en) | 2022-03-09 | 2023-09-14 | Selecta Biosciences, Inc. | Immunosuppressants in combination with anti-igm agents and related dosing |
| US20230381277A1 (en) | 2022-04-08 | 2023-11-30 | Selecta Biosciences, Inc. | High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance |
| US20240148841A1 (en) | 2022-08-11 | 2024-05-09 | Selecta Biosciences Inc. | Compositions and methods related to immunoglobulin proteases and fusions thereof |
| WO2024107889A1 (en) | 2022-11-15 | 2024-05-23 | Selecta Biosciences, Inc. | Compositions and methods for treating primary biliary cholangitis |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US7288266B2 (en) | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6187335B1 (en) | 1997-12-31 | 2001-02-13 | Orasomal Technologies, Inc. | Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| EP1100464A1 (en) | 1998-07-31 | 2001-05-23 | Korea Institute Of Science And Technology | Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier |
| WO2000012125A1 (en) * | 1998-09-01 | 2000-03-09 | Elan Corporation, Plc | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| US20040038303A1 (en) * | 2002-04-08 | 2004-02-26 | Unger Gretchen M. | Biologic modulations with nanoparticles |
| US20050232984A1 (en) | 2002-08-23 | 2005-10-20 | Heinrich Haas | Non-vesicular cationic lipid formulations |
| CN1886100A (zh) * | 2003-11-14 | 2006-12-27 | 阿尔萨公司 | 基于表面活性剂的凝胶作为可注射的持续药物递送载体 |
| US20050260260A1 (en) | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
| NZ566705A (en) * | 2005-08-31 | 2011-06-30 | Abraxis Bioscience Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US8414910B2 (en) * | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| BRPI0817664A2 (pt) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
| US8613951B2 (en) * | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| SI2774608T1 (sl) * | 2008-06-16 | 2020-02-28 | Pfizer Inc. | Polimerni nanodelci, napolnjeni z zdravilom, ter postopki za njihovo pripravo in uporabo |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| ES2776126T3 (es) * | 2008-12-15 | 2020-07-29 | Pfizer | Nanopartículas de circulación prolongada para la liberación sostenida de agentes terapéuticos |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| US9757456B2 (en) * | 2010-09-14 | 2017-09-12 | Nanologica Ab | Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients and suppression of crystallization of pharmaceutical active ingredients |
| WO2012059936A1 (en) * | 2010-11-03 | 2012-05-10 | Padma Venkitachalam Devarajan | Pharmaceutical compositions for colloidal drug delivery |
| US9289476B2 (en) * | 2011-04-29 | 2016-03-22 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| CN102793674B (zh) * | 2011-05-26 | 2014-11-26 | 澳门科技大学 | 一种雷公藤甲素固体脂质纳米颗粒及其制备方法和应用 |
| AU2012323937A1 (en) | 2011-10-14 | 2014-06-05 | Stc.Unm | Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| CN102871966B (zh) * | 2012-10-19 | 2013-11-20 | 东南大学 | 用于改善雷帕霉素生物利用度的纳米载药颗粒及其制备方法 |
-
2015
- 2015-11-05 WO PCT/US2015/059350 patent/WO2016073799A1/en active Application Filing
- 2015-11-05 JP JP2017524450A patent/JP6912377B2/ja active Active
- 2015-11-05 HU HUE15857076A patent/HUE054894T2/hu unknown
- 2015-11-05 BR BR112017008720A patent/BR112017008720A2/pt not_active Application Discontinuation
- 2015-11-05 EP EP20204014.3A patent/EP3834823B1/en active Active
- 2015-11-05 EA EA201790978A patent/EA201790978A1/ru unknown
- 2015-11-05 FI FIEP20204014.3T patent/FI3834823T3/fi active
- 2015-11-05 EP EP23220853.8A patent/EP4360633A3/en active Pending
- 2015-11-05 MX MX2017005904A patent/MX2017005904A/es unknown
- 2015-11-05 BR BR122021025344-7A patent/BR122021025344B1/pt active IP Right Grant
- 2015-11-05 CN CN202110403075.4A patent/CN113244191A/zh active Pending
- 2015-11-05 ES ES15798601T patent/ES2846809T3/es active Active
- 2015-11-05 CN CN201580059855.4A patent/CN107072964A/zh active Pending
- 2015-11-05 DK DK21156943.9T patent/DK3906918T3/da active
- 2015-11-05 JP JP2017524451A patent/JP7218089B2/ja active Active
- 2015-11-05 AU AU2015342969A patent/AU2015342969B2/en active Active
- 2015-11-05 EP EP15857076.2A patent/EP3215192B1/en active Active
- 2015-11-05 FI FIEP21156943.9T patent/FI3906918T3/fi active
- 2015-11-05 EP EP15798601.9A patent/EP3215133B1/en active Active
- 2015-11-05 BR BR112017008499-6A patent/BR112017008499B1/pt active IP Right Grant
- 2015-11-05 CA CA2966850A patent/CA2966850C/en active Active
- 2015-11-05 HU HUE15798601A patent/HUE053094T2/hu unknown
- 2015-11-05 CN CN202210754468.4A patent/CN115212186A/zh active Pending
- 2015-11-05 CN CN201580060789.2A patent/CN107072965B/zh active Active
- 2015-11-05 IL IL296246A patent/IL296246A/en unknown
- 2015-11-05 WO PCT/US2015/059349 patent/WO2016073798A1/en active Application Filing
- 2015-11-05 HU HUE20204014A patent/HUE066099T2/hu unknown
- 2015-11-05 IL IL295292A patent/IL295292B1/en unknown
- 2015-11-05 DK DK15857076.2T patent/DK3215192T3/da active
- 2015-11-05 ES ES15857076T patent/ES2865375T3/es active Active
- 2015-11-05 US US14/934,135 patent/US20160128987A1/en active Pending
- 2015-11-05 PT PT157986019T patent/PT3215133T/pt unknown
- 2015-11-05 PL PL15798601T patent/PL3215133T3/pl unknown
- 2015-11-05 EP EP23220845.4A patent/EP4356910A3/en active Pending
- 2015-11-05 CA CA2966852A patent/CA2966852C/en active Active
- 2015-11-05 EA EA201790977A patent/EA201790977A1/ru unknown
- 2015-11-05 CN CN202210754573.8A patent/CN115212187A/zh active Pending
- 2015-11-05 AU AU2015342968A patent/AU2015342968B2/en active Active
- 2015-11-05 DK DK20204014.3T patent/DK3834823T3/da active
- 2015-11-05 US US14/934,132 patent/US20160128986A1/en active Pending
- 2015-11-05 RS RS20210097A patent/RS61359B1/sr unknown
- 2015-11-05 IL IL283699A patent/IL283699B/en unknown
- 2015-11-05 SI SI201531494T patent/SI3215133T1/sl unknown
- 2015-11-05 LT LTEP15798601.9T patent/LT3215133T/lt unknown
- 2015-11-05 MX MX2017005903A patent/MX2017005903A/es unknown
- 2015-11-05 EP EP21156943.9A patent/EP3906918B1/en active Active
- 2015-11-05 KR KR1020177014830A patent/KR102656139B1/ko active IP Right Grant
- 2015-11-05 KR KR1020177014831A patent/KR102601922B1/ko active IP Right Grant
- 2015-11-05 DK DK15798601.9T patent/DK3215133T3/da active
-
2017
- 2017-04-06 IL IL251622A patent/IL251622B/en active IP Right Grant
- 2017-04-06 IL IL251620A patent/IL251620B/en active IP Right Grant
- 2017-05-04 MX MX2021012273A patent/MX2021012273A/es unknown
- 2017-05-04 MX MX2021006698A patent/MX2021006698A/es unknown
-
2021
- 2021-01-20 HR HRP20210098TT patent/HRP20210098T1/hr unknown
- 2021-01-27 CY CY20211100063T patent/CY1124418T1/el unknown
- 2021-01-31 IL IL280518A patent/IL280518B/en unknown
- 2021-05-10 JP JP2021080003A patent/JP2021143180A/ja active Pending
- 2021-07-27 AU AU2021209202A patent/AU2021209202B2/en active Active
- 2021-07-27 AU AU2021209204A patent/AU2021209204A1/en not_active Abandoned
- 2021-12-02 IL IL288609A patent/IL288609B2/en unknown
-
2022
- 2022-09-01 JP JP2022139392A patent/JP2022173236A/ja active Pending
-
2023
- 2023-07-03 JP JP2023109379A patent/JP2023169893A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3215133T3 (da) | Fremgangsmåder og sammensætninger relateret til anvendelsen af overfladeaktive stoffer med lav hlb ved fremstilling af syntetiske nanobærere, som omfatter en rapalog | |
| IL266560A (en) | Endophytes, related preparations and methods of using them | |
| BR112016030787A2 (pt) | entidade química, composição farmacêutica e seu uso | |
| CL2016002569A1 (es) | Anticuerpos, composiciones farmacéuticas y usos de los mismos | |
| DK3206715T3 (da) | Anvendelse af cannabidiol i behandling af tuberøs sklerosekompleks | |
| BR112016015706A2 (pt) | composto, uso do mesmo e composição farmacêutica | |
| GB201411197D0 (en) | Composition and use thereof | |
| HUE052359T2 (hu) | Hidrofluorolefin-bázisú készítmény és alkalmazása | |
| IL249646A0 (en) | Platinum compounds, preparations, and their uses | |
| DK3268013T3 (da) | Il-10-producerende cd4+-t-celler til anvendelse ved behandling af en cancer | |
| LT3223796T (lt) | Farmacinės kompozicijos, jų gamyba ir panaudojimo būdai | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
| LT3229843T (lt) | Farmacinė kompozicija, jos paruošimo būdas ir naudojimas | |
| ZA201706254B (en) | Oil blends, processes for the preparation thereof and their use in formulas | |
| IL247531A0 (en) | The history of ksuz, their preparation and uses | |
| DK3229790T3 (da) | Sammensætninger omfattende mediumkæde triglycerider til anvendelse i behandlingen af epilepsi | |
| DK3125865T3 (da) | Samling af aktive ingredienser til topikal anvendelse i restrukturering af ændret kutanbarriere følgende hudsygdomme | |
| GB201411196D0 (en) | Composition and use thereof | |
| DK3290023T3 (da) | Farmaceutisk sammensætning med langvarig frigivelse, som indeholder rivastigmin | |
| HK1231496A1 (zh) | 基於 的支架組合物、方法和應用 | |
| DK3359183T3 (da) | Polyepitop-konstrukter til anvendelse i immunoterapy | |
| TH1501007100A (th) | องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน | |
| TH1601003209A (th) | องค์ประกอบเครื่องสำอางที่เป็นผง |